Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Hyloris Pharmaceuticals SA
  6. Financials
    HYL   BE0974363955

HYLORIS PHARMACEUTICALS SA

(HYL)
  Report
Real-time Euronext Bruxelles  -  10:04 2022-12-07 am EST
13.38 EUR   -0.15%
11/23Hyloris Pharmaceuticals Develops New Treatment For Idiopathic Rhinitis
MT
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
GL
11/22Hyloris Pharmaceuticals Broadens Pipeline with a Nasal Product Candidate for Idiopathic Rhinitis
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
Valuation
Fiscal Period: December 2020 2021 2022 2023 2024
Capitalization1 245447359--
Enterprise Value (EV)1 182409333347347
P/E ratio -28,8x-38,4x-29,8x-37,2x39,4x
Yield -----
Capitalization / Revenue 1 402x144x71,8x32,6x8,26x
EV / Revenue 1 038x132x66,6x31,6x7,98x
EV / EBITDA -40,4x-88,2x-29,2x-38,6x31,6x
Price to Book -9,30x9,93x13,7x10,1x
Nbr of stocks (in thousands) 25 83325 83326 800--
Reference price (EUR) 9,5017,313,413,413,4
Announcement Date 03/09/202103/16/2022---
1 EUR in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales1 0,090,183,105,0011,043,5
EBITDA1 --4,49-4,63-11,4-9,0011,0
Operating profit (EBIT)1 --5,08-10,5-12,0-9,0010,0
Operating Margin --2 900%-340%-240%-81,8%23,0%
Pre-Tax Profit (EBT)1 --7,15-11,3-12,0-9,0010,0
Net income1 --7,15-11,6-12,0-9,609,00
Net margin --4 083%-374%-240%-87,3%20,7%
EPS2 -1,49-0,33-0,45-0,45-0,360,34
Dividend per Share2 ------
Announcement Date 06/16/202003/09/202103/16/2022---
1 EUR in Million
2 EUR
Estimates
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2022 S1
Net sales1 1,03
EBITDA -
Operating profit (EBIT) -
Operating Margin -
Pre-Tax Profit (EBT) -
Net income -
Net margin -
EPS -
Dividend per Share -
Announcement Date 09/01/2022
1 EUR in Million
Balance Sheet Analysis
Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt1 ------
Net Cash position1 -63,838,326,012,012,0
Leverage (Debt / EBITDA) -14,2x8,25x2,28x1,33x-1,09x
Free Cash Flow ------
ROE (Net Profit / Equities) ------
Shareholders' equity1 ------
ROA (Net Profit / Asset) ------
Assets1 ------
Book Value Per Share2 --1,861,350,981,33
Cash Flow per Share ------
Capex1 --1,060,502,001,50
Capex / Sales --34,3%10,0%18,2%3,45%
Announcement Date 06/16/202003/09/202103/16/2022---
1 EUR in Million
2 EUR
Estimates
Key data
Capitalization (EUR) 359 125 011
Capitalization (USD) 377 787 725
Net sales (EUR) 3 096 000
Net sales (USD) 3 256 890
Number of employees 21
Sales / Employee (EUR) 147 429
Sales / Employee (USD) 155 090
Free-Float 52,2%
Free-Float capitalization (EUR) 187 473 725
Free-Float capitalization (USD) 197 216 206
Avg. Exchange 20 sessions (EUR) 32 310
Avg. Exchange 20 sessions (USD) 33 989
Average Daily Capital Traded 0,01%
EPS & Dividend